Contents

Current Cancer Drug Targets, Volume 3 - Number 5

Preface [Hot topic:Hsp90 Molecular Chaperone Inhibitors: Opportunities and Challenges (Guest Editor: Paul Workman)]

, 3(5): i

Paul Workman


DOI: 10.2174/1568009033481840




Overview: Translating Hsp90 Biology into Hsp90 Drugs

, 3(5): 297 - 300

Paul Workman


DOI: 10.2174/1568009033481868




Structure and Functional Relationships of Hsp90

, 3(5): 301 - 323

Chrisostomos Prodromou and Laurence H. Pearl


DOI: 10.2174/1568009033481877




Natural Product Origins of Hsp90 Inhibitors

, 3(5): 325 - 330

Yoshimasa Uehara


DOI: 10.2174/1568009033481796




Genes and Proteins Governing the Cellular Sensitivity to HSP90 Inhibitors: A Mechanistic Perspective

, 3(5): 331 - 341

Alison Maloney, Paul A. Clarke and Paul Workman


DOI: 10.2174/1568009033481822




The C-Terminal Half of Heat Shock Protein 90 Represents a Second Site for Pharmacologic Intervention in Chaperone Function

, 3(5): 343 - 347

Monica G. Marcu and Leonard M. Neckers


DOI: 10.2174/1568009033481804




The Stress Response: Implications for the Clinical Development of Hsp90 Inhibitors

, 3(5): 349 - 358

Luke Whitesell, Rochelle Bagatell and Ryan Falsey


DOI: 10.2174/1568009033481787




Development of Radicicol Analogues

, 3(5): 359 - 369

Shiro Soga, Yukimasa Shiotsu, Shiro Akinaga and Sreenath V. Sharma


DOI: 10.2174/1568009033481859




Development of Purine-Scaffold Small Molecule Inhibitors of Hsp90

, 3(5): 371 - 376

Gabriela Chiosis, Brian Lucas, Henri Huezo, David Solit, Andrea Basso and Neal Rosen


DOI: 10.2174/1568009033481778




Clinical Development of 17-Allylamino, 17-Demethoxygeldanamycin

, 3(5): 377 - 383

Edward A. Sausville, Joseph E. Tomaszewski and Percy Ivy


DOI: 10.2174/1568009033481831




The Clinical Applications of Heat Shock Protein Inhibitors in Cancer - Present and Future

, 3(5): 385 - 390

Udai Banerji, Ian Judson and Paul Workman


DOI: 10.2174/1568009033481813




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science